Cargando…

Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature

Facioscapulohumeral muscular dystrophy (FSHD) is an inherited myopathy affecting approximately 1 in 7500 individuals worldwide. It is a progressive disease characterised by skeletal muscle weakness and wasting. A genetic mutation on the 4q35 chromosome results in the expression of the double homeobo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denny, Adam Philip, Heather, Alison Kay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485364/ https://www.ncbi.nlm.nih.gov/pubmed/28690764 http://dx.doi.org/10.1155/2017/7020295

Ejemplares similares

Genotype-phenotype correlations in FSHD
por: Zernov, Nikolay, et al.
Publicado: (2019)

Current Therapeutic Approaches in FSHD
por: Wang, Leo H., et al.
Publicado: (2021)

Does DNA Methylation Matter in FSHD?
por: Salsi, Valentina, et al.
Publicado: (2020)

Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020)

FSHD: copy number variations on the theme of muscular dystrophy
por: Cabianca, Daphne Selvaggia, et al.
Publicado: (2010)

Meeting report: the 2021 FSHD International Research Congress
por: Jagannathan, Sujatha, et al.
Publicado: (2022)

FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
por: Himeda, Charis L., et al.
Publicado: (2022)

Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD): A Systematic Review
por: Aguirre, Alex S, et al.
Publicado: (2023)

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2021)

DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2021)

Update on the Molecular Aspects and Methods Underlying the Complex Architecture of FSHD
por: Caputo, Valerio, et al.
Publicado: (2022)

Precise Epigenetic Analysis Using Targeted Bisulfite Genomic Sequencing Distinguishes FSHD1, FSHD2, and Healthy Subjects
por: Gould, Taylor, et al.
Publicado: (2021)

Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
por: Joubert, Romains, et al.
Publicado: (2020)

Gene expression during normal and FSHD myogenesis
por: Tsumagari, Koji, et al.
Publicado: (2011)

Expression Profiling of FSHD-1 and FSHD-2 Cells during Myogenic Differentiation Evidences Common and Distinctive Gene Dysregulation Patterns
por: Cheli, Stefania, et al.
Publicado: (2011)

Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Ducharme-Smith, Allison, et al.
Publicado: (2021)

DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation
por: Banerji, Christopher R S, et al.
Publicado: (2020)

DUX4 Expression in FSHD Muscles: Focus on Its mRNA Regulation
por: Sidlauskaite, Eva, et al.
Publicado: (2020)

FSHD Myotubes with Different Phenotypes Exhibit Distinct Proteomes
por: Tassin, Alexandra, et al.
Publicado: (2012)

Functional domains of the FSHD-associated DUX4 protein
por: Mitsuhashi, Hiroaki, et al.
Publicado: (2018)

Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD
por: Wallace, Lindsay M., et al.
Publicado: (2017)

UK Facioscapulohumeral Muscular Dystrophy (FSHD) Patient Registry
por: Wood, Libby, et al.
Publicado: (2014)

Meeting report: the 2020 FSHD International Research Congress
por: Kyba, Michael, et al.
Publicado: (2020)

The FSHD jigsaw: are we placing the tiles in the right position?
por: Salsi, Valentina, et al.
Publicado: (2023)

An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy
por: Cowley, Matthew V, et al.
Publicado: (2023)

Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts
por: Pandey, Sachchida Nand, et al.
Publicado: (2015)

Orofacial Muscle Weakening in Facioscapulohumeral Muscular Dystrophy (FSHD) Patients
por: Konstantonis, Dimitrios, et al.
Publicado: (2022)

The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression
por: Vanderplanck, Céline, et al.
Publicado: (2011)

Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation
por: Bodega, Beatrice, et al.
Publicado: (2009)

Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes
por: Rashnonejad, Afrooz, et al.
Publicado: (2020)

Facioscapulohumeral muscular dystrophy (FSHD) and multiple sclerosis: a case report
por: Iodice, Rosa, et al.
Publicado: (2020)

Gastrointestinal cancer occurs as extramuscular manifestation in FSHD1 patients
por: Kurashige, Takashi, et al.
Publicado: (2022)

FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1
por: Mellion, M., et al.
Publicado: (2020)

Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review
por: Białczyk, Aleksandra, et al.
Publicado: (2023)

Direct interplay between two candidate genes in FSHD muscular dystrophy
por: Ferri, Giulia, et al.
Publicado: (2015)

MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy
por: Runfola, Valeria, et al.
Publicado: (2023)

PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level
por: Banerji, Christopher R S, et al.
Publicado: (2019)

miRNA Expression in Control and FSHD Fetal Human Muscle Biopsies
por: Portilho, Débora Morueco, et al.
Publicado: (2015)

The variability of SMCHD1 gene in FSHD patients: evidence of new mutations
por: Strafella, Claudia, et al.
Publicado: (2019)

Anticipation Avoids Adversity: Anesthetic Management of a Case of Facioscapulohumeral Dystrophy (FSHD)
por: Ahamed, Seyed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3in07iar4vhtqqh7ci8modsvst